Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bridge Bio Doses First Patient in Phase II Trial of ATX Inhibitor for Fibrosis

publication date: Apr 13, 2023

Bridge Biotherapeutics has dosed the first patient in a global Phase IIa trial of its autotaxin (ATX) inhibitor to evaluate the efficacy, safety and tolerability of the candidate in patients with idiopathic pulmonary fibrosis (IPF). In 2019, Bridge completed a Phase I trial of BBT-877 showing it could inhibit lysophosphatidic acid (LPA) production by as much as 90%. LPA is known to bind to cell receptors and induce physiological activities that lead to fibrotic disease development, including IPF. Bridge, a company with Korean, US and China operations, discovers and develops novel therapeutics for ulcerative colitis, fibrotic disease and cancers. More details....

Stock Symbol: (KQ288330)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital